Cover Image
市場調查報告書

腎絲球腎炎的開發中產品分析

Glomerulonephritis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192609
出版日期 內容資訊 英文 124 Pages
訂單完成後即時交付
價格
Back to Top
腎絲球腎炎的開發中產品分析 Glomerulonephritis - Pipeline Review, H2 2016
出版日期: 2016年09月14日 內容資訊: 英文 124 Pages
簡介

腎絲球腎炎 (GN,腎小球腎炎) 是腎臟疾病的一種,特徵是會引起腎臟的腎小球發炎。腎絲球腎炎的要因有喉嚨感染鏈球菌 (鏈球菌性咽頭炎) ,免疫疾病 (狼瘡等) 、第一型·第二型糖尿病,各種病毒 (HIV,B型肝炎,C型肝炎另外) 等。提高感染率的要因有家族感染病史、主要病因的存在、高血壓等。一般的症狀有尿中有血 (尿為黑色/紅鏽顏色/紅色的) ,及泡沫狀尿,臉·眼·腳後跟·腳·腳·腹部腫脹 (水腫) 等。治療方法由於疾病要素而不相同,有藥物療法和改善生活習慣,透析,腎臟移植等。

本報告提供全球各國治療腎絲球腎炎所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

腎絲球腎炎概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

腎絲球腎炎:企業開發中的治療藥

腎絲球腎炎:大學/機關研究中的治療藥

腎絲球腎炎:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

腎絲球腎炎:企業開發中的產品

腎絲球腎炎:大學/機關研究中的產品

腎絲球腎炎的治療藥的開發企業

  • Adienne Pharma & Biotech
  • Alexion Pharmaceuticals, Inc.
  • Anthera Pharmaceuticals, Inc.
  • Avexxin AS
  • Biogen, Inc.
  • Cyclacel Pharmaceuticals, Inc.
  • FibroStatin SL
  • Fortress Biotech, Inc.
  • GlaxoSmithKline Plc
  • Hansa Medical AB
  • Mallinckrodt Plc
  • Pfizer Inc.
  • Pharmalink AB
  • Rigel Pharmaceuticals, Inc.
  • Toray Industries Industries, Inc.

腎絲球腎炎:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • Adipose Stem Cell Therapy for IgA Nephropathy
  • AVX-235
  • belimumab
  • blisibimod
  • budesonide
  • corticotropin
  • DEXM-74
  • Drug to Inhibit GPBP for Glomerulonephritis and Cancer
  • eculizumab
  • Endoglycosidase of Streptococcus pyogenes
  • fostamatinib disodium
  • Mubodina
  • PBF-1472
  • PF-1355
  • Recombinant Enzyme for Immunoglobulin A Nephropathy
  • rituximab
  • seliciclib
  • Small Molecule to Inhibit Vitamin K Epoxide Reductase for Glomerulonephritis
  • Vaccine to Target CD40 for Membranous Glomerulonephritis

腎絲球腎炎:最近的開發平台趨勢

腎絲球腎炎:暫停中的計劃

腎絲球腎炎:開發中止的產品

腎絲球腎炎:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8454IDB

Summary

Global Markets Direct's, 'Glomerulonephritis - Pipeline Review, H2 2016', provides an overview of the Glomerulonephritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Glomerulonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Glomerulonephritis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Glomerulonephritis
  • The report reviews pipeline therapeutics for Glomerulonephritis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Glomerulonephritis therapeutics and enlists all their major and minor projects
  • The report assesses Glomerulonephritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Glomerulonephritis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Glomerulonephritis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glomerulonephritis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Glomerulonephritis Overview
  • Therapeutics Development
    • Pipeline Products for Glomerulonephritis - Overview
    • Pipeline Products for Glomerulonephritis - Comparative Analysis
  • Glomerulonephritis - Therapeutics under Development by Companies
  • Glomerulonephritis - Therapeutics under Investigation by Universities/Institutes
  • Glomerulonephritis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Glomerulonephritis - Products under Development by Companies
  • Glomerulonephritis - Products under Investigation by Universities/Institutes
  • Glomerulonephritis - Companies Involved in Therapeutics Development
    • Achillion Pharmaceuticals, Inc.
    • Alexion Pharmaceuticals Inc
    • Amyndas Pharmaceuticals LLC
    • Anthera Pharmaceuticals Inc
    • Avexxin AS
    • Biogen Inc
    • Complexa, Inc.
    • Dimerix Bioscience Pty Ltd
    • GlaxoSmithKline Plc
    • Mallinckrodt Plc
    • Omeros Corporation
    • Pfizer Inc.
    • Pharmalink AB
    • Retrophin Inc.
    • Rigel Pharmaceuticals, Inc.
    • Shire Plc
    • Toray Industries, Inc.
    • Variant Pharmaceuticals, Inc.
  • Glomerulonephritis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (irbesartan + propagermanium) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACH-4471 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AMY-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVX-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • belimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • blisibimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • budesonide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • corticotropin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CXA-10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eculizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fostamatinib disodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • losmapimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit Glycoprotein Ib Alpha for Vasculitis and Glomerulonephritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMS-721 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-1355 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Enzyme for Immunoglobulin A Nephropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rituximab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SHP-627 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Vitamin K Epoxide Reductase for Glomerulonephritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sparsentan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TM-5484 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target CD40 for Membranous Glomerulonephritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VAR-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Glomerulonephritis - Dormant Projects
  • Glomerulonephritis - Discontinued Products
  • Glomerulonephritis - Product Development Milestones
    • Featured News & Press Releases
      • Aug 01, 2016: Dimerix announces outcomes of DMX-200 pre-IND meeting with the FDA
      • May 17, 2016: First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel for Rare Cause of Nephrotic Syndrome
      • Mar 30, 2016: Retrophin Completes Enrollment of Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis
      • Mar 04, 2016: Amyndas' lead candidate AMY-101 receives orphan drug status from the FDA and the EMA for the treatment of C3 glomerulopathy
      • Dec 14, 2015: Dimerix receives Orphan Designation for its lead drug candidate targeting patients with chronic kidney disease
      • Nov 16, 2015: Retrophin Receives European Orphan Drug Designation for Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis
      • Jan 09, 2015: Ligand Partner Retrophin Receives Orphan Drug Designation for Sparsentan
      • Feb 25, 2013: Ligand Receives $1.4m Milestone Payment From Retrophin
      • Jan 09, 2013: Ligand Receives Equity Milestone Payment From Retrophin
      • Oct 31, 2012: Pharmalink Signs Manufacturing Agreement For Nefecon
      • Oct 13, 2010: Pharmalink Receives US Orphan Drug Designation For Nefecon
      • Oct 26, 2009: Japanese Patent granted for Pharmalink AB's Nefecon
      • Apr 29, 2009: Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon
      • Mar 31, 2008: Pharmalink Reports Promising Interim Results From Phase II Trials For New Renal Disease Drug Nefecon
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Glomerulonephritis, H2 2016
  • Number of Products under Development for Glomerulonephritis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Glomerulonephritis - Pipeline by Achillion Pharmaceuticals, Inc., H2 2016
  • Glomerulonephritis - Pipeline by Alexion Pharmaceuticals Inc, H2 2016
  • Glomerulonephritis - Pipeline by Amyndas Pharmaceuticals LLC, H2 2016
  • Glomerulonephritis - Pipeline by Anthera Pharmaceuticals Inc, H2 2016
  • Glomerulonephritis - Pipeline by Avexxin AS, H2 2016
  • Glomerulonephritis - Pipeline by Biogen Inc, H2 2016
  • Glomerulonephritis - Pipeline by Complexa, Inc., H2 2016
  • Glomerulonephritis - Pipeline by Dimerix Bioscience Pty Ltd, H2 2016
  • Glomerulonephritis - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Glomerulonephritis - Pipeline by Mallinckrodt Plc, H2 2016
  • Glomerulonephritis - Pipeline by Omeros Corporation, H2 2016
  • Glomerulonephritis - Pipeline by Pfizer Inc., H2 2016
  • Glomerulonephritis - Pipeline by Pharmalink AB, H2 2016
  • Glomerulonephritis - Pipeline by Retrophin Inc., H2 2016
  • Glomerulonephritis - Pipeline by Rigel Pharmaceuticals, Inc., H2 2016
  • Glomerulonephritis - Pipeline by Shire Plc, H2 2016
  • Glomerulonephritis - Pipeline by Toray Industries, Inc., H2 2016
  • Glomerulonephritis - Pipeline by Variant Pharmaceuticals, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Glomerulonephritis - Dormant Projects, H2 2016
  • Glomerulonephritis - Dormant Projects (Contd..1), H2 2016
  • Glomerulonephritis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Glomerulonephritis, H2 2016
  • Number of Products under Development for Glomerulonephritis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top